Intellectual property

Mucosis considers patents and proprietary know-how to be critical assets of our company. We protect our scientific findings and inventions by filing patents in all major markets in America, Europe and Asia and by keeping non-patentable know how as trade secret. Our Mimopath® technology is broadly protected by a number of patents families that include over 20 granted and in-process patents. Moreover, we’ve registered numerous trademarks for our technology and products.

 

coherent strong patent portfolio

07.11.16 Mucosis Initiates First-in-Human Study of SynGEM®, a Needle-Free Nasal Spray RSV Vaccine
more >

24.03.16 Mucosis to Present at World Vaccines Congress 2016
more >

20.01.16 Mucosis Secures €3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London
more >

19.05.15 Mucosis to Present Data on Intranasal RSV Vaccine SynGEM® at Modern Vaccines Adjuvants & Delivery Systems 2015
more >

23.03.15 Mucosis to Present on Intranasal Respiratory Syncytial Virus Vaccine Candidate SynGEM® at BioCapital Europe
more >

10.11.14 Mucosis Presents Data on Intranasal Respiratory Syncytial Virus Vaccine SynGEM® at RSV2014 Symposium
more >

20.10.14 Mucosis Presents Data on Intranasal RSV Vaccine SynGEM® at Vaccines 2014 Conference
more >